Biotech startups that raised Series B in San Diego, California
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Mirador Therapeutics | San Diego | Series B | $250.0M | 2026-01-12 |
| BlossomHill Therapeutics | San Diego | Series B | $84.0M | 2025-12-10 |
| Avenzo Therapeutics | San Diego | Series B | $60.0M | 2025-09-04 |
| Actio Biosciences | San Diego | Series B | $66.0M | 2025-06-18 |
| Sirius Therapeutics | San Diego | Series B | $50.0M | 2025-05-09 |
| Gallant | San Diego | Series B | $18.0M | 2025-03-15 |
| Human Longevity | San Diego | Series B | $39.8M | 2024-08-21 |
| Kate Therapeutics | San Diego | Series B | $21.8M | 2024-08-07 |
8 rows of the CSV in 5 of its 18 columns.
- The 53 biotech startups in San Diego, California whose last round is Series B have raised $6.7B in total.
- 11 of them closed their most recent round in the last 12 months, $1.0B combined.
- The largest of those rounds is Mirador Therapeutics' $250.0M Series B, dated January 2026.
- The most recent is KymaThera's $80.0M Series B on 6 October 2026.
- OrbiMed is an investor in 5 of them, more than any other fund.
- Health care is the most common other sector, with 49 companies (92%).
- 32% were founded in 2020 or later; the median founding year is 2017.
- The most common team size is 11 to 50 employees (62% of companies with a recorded size).
- 1 is a unicorn, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
10 of 53| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| Mirador Therapeutics | Mirador Therapeutics develops precision medicines for immune-mediated diseases. | Biotech | Series B | $250.0M | 2026-01-12 | $730.0M | OrbiMed, Fidelity, ARCH Venture Partners +1 | 11 to 50 | 2024 |
| BlossomHill Therapeutics | BlossomHill Therapeutics is a biopharmaceutical company focused on oncology and autoimmune disorders. | Biotech | Series B | $84.0M | 2025-12-10 | $257.0M | OrbiMed, Cormorant Asset Management, Vivo Capital +2 | 11 to 50 | 2020 |
| Avenzo Therapeutics | Avenzo Therapeutics develops oncology therapies for treating cancer. | Biotech | Series B | $60.0M | 2025-09-04 | $841.9M | New Enterprise Associates, Sands Capital Ventures, Lilly Asia Ventures +2 | 11 to 50 | 2022 |
| Actio Biosciences | Actio Biosciences develops drugs for rare diseases through its research center. | Biotech | Series B | $66.0M | 2025-06-18 | $121.0M | Canaan Partners, Euclidean Capital, Deerfield Management +2 | 11 to 50 | 2021 |
| Sirius Therapeutics | Sirius Therapeutics is a biotechnology company developing RNAi therapies for cardiovascular diseases. | Biotech | Series B | $50.0M | 2025-05-09 | $110.0M | OrbiMed, Hankang Capital, Creacion Ventures +1 | 11 to 50 | 2021 |
| Gallant | Gallant advances investigational stem cell therapies to extend the healthy years of pets. | Biotech | Series B | $18.0M | 2025-03-15 | $44.0M | Alumni Ventures, Bling Capital, Science +2 | 11 to 50 | 2018 |
| Human Longevity Unicorn | Human Longevity is a genomics-based health intelligence company supporting proactive healthcare. | Biotech | Series B | $39.8M | 2024-08-21 | $369.8M | StartUp Health, Amino Capital, Threshold +1 | 51 to 100 | 2013 |
| Capstan Therapeutics | Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases. | Biotech | Series B | $175.0M | 2024-03-20 | $340.0M | RA Capital Management, OrbiMed, Alexandria Venture Investments +2 | 101 to 250 | 2021 |
| MBrace Therapeutics | MBrace Therapeutics is a privately held biopharmaceutical company. | Biotech | Series B | $85.0M | 2023-11-14 | $110.0M | Venrock, TPG, Alta Partners +2 | 11 to 50 | 2019 |
| Tentarix Biotherapeutics | Tentarix Biotherapeutics creates protein therapeutics with combined bioactivities using synthetic biology. | Biotech | Series B | $35.0M | 2023-09-06 | $93.0M | Versant Ventures, Samsara BioCapital, Amplitude Venture Capital | 11 to 50 | 2020 |
Table 1. Biotech startups that raised Series B in San Diego, California: the 10 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 53.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Mirador Therapeutics | Mirador Therapeutics develops precision medicines for immune-mediated diseases. | Biotech | Series B | $250.0M | 2026-01-12 | $730.0M | OrbiMed, Fidelity, ARCH Venture Partners +1 | 11 to 50 | 2024 |
| 2 | BlossomHill Therapeutics | BlossomHill Therapeutics is a biopharmaceutical company focused on oncology and autoimmune disorders. | Biotech | Series B | $84.0M | 2025-12-10 | $257.0M | OrbiMed, Cormorant Asset Management, Vivo Capital +2 | 11 to 50 | 2020 |
Table 2. Biotech startups that raised Series B in San Diego, California: the 2 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | OrbiMed | Private equity firm | New York, United States | 5 | 9% | 2 | Mirador Therapeutics, BlossomHill Therapeutics |
| 2 | Blue Owl | Private equity firm | New York, United States | 2 | 4% | 1 | Mirador Therapeutics |
| 3 | Digitalis Ventures | Venture capital firm | New York, United States | 2 | 4% | ||
| 4 | Bold Capital Partners | Venture capital firm | Santa Monica, United States | 2 | 4% | ||
| 5 | Versant Ventures | Venture capital firm | Menlo Park, United States | 2 | 4% | ||
| 6 | Alta Partners | Venture capital firm | Jackson, United States | 2 | 4% | ||
| 7 | ARCH Venture Partners | Venture capital firm | Chicago, United States | 1 | 2% | 1 | Mirador Therapeutics |
| 8 | Fidelity | Investment bank | Boston, United States | 1 | 2% | 1 | Mirador Therapeutics |
| 9 | Cormorant Asset Management | Hedge fund | Boston, United States | 1 | 2% | 1 | BlossomHill Therapeutics |
| 10 | Colt Ventures | Family office | Dallas, United States | 1 | 2% | 1 | BlossomHill Therapeutics |
| 11 | Plaisance Capital Management | Entrepreneurship program | Natick, United States | 1 | 2% | 1 | BlossomHill Therapeutics |
| 12 | Vivo Capital | Private equity firm | Palo Alto, United States | 1 | 2% | 1 | BlossomHill Therapeutics |
| 13 | Lilly Asia Ventures | Venture capital firm | Shanghai, China | 1 | 2% | ||
| 14 | Deep Track Capital | Hedge fund | Greenwich, United States | 1 | 2% | ||
| 15 | INCE Capital | Venture capital firm | Pudong, China | 1 | 2% |
Table 3. Biotech startups that raised Series B in San Diego, California: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 49 | 92% | $6.6B |
| Software | 2 | 4% | $52.7M |
| Artificial intelligence | 1 | 2% | $52.7M |
Table 4. Biotech startups that raised Series B in San Diego, California by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series B | 53 | 100% | $45.0M |
Table 5. Biotech startups that raised Series B in San Diego, California by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 1 | 9% | $80.0M |
| August 2026 | 2 | 18% | $76.0M |
| July 2026 | 2 | 18% | $130.0M |
| April 2026 | 2 | 18% | $237.0M |
| January 2026 | 2 | 18% | $273.3M |
| December 2025 | 2 | 18% | $214.0M |
Table 6. Biotech startups that raised Series B in San Diego, California: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 9 | 17% | $796.3M |
| 2025 | 7 | 13% | $426.0M |
| 2024 | 7 | 13% | $600.6M |
| 2023 | 4 | 8% | $250.2M |
| 2022 | 2 | 4% | $52.0M |
| 2021 | 5 | 9% | $276.0M |
Table 7. Biotech startups that raised Series B in San Diego, California by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 5 | 9% |
| 2020 to 2022 | 12 | 23% |
| 2015 to 2019 | 14 | 26% |
| 2010 to 2014 | 9 | 17% |
| Before 2010 | 13 | 25% |
Table 8. Biotech startups that raised Series B in San Diego, California by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 8 | 15% |
| 11 to 50 | 33 | 62% |
| 51 to 100 | 7 | 13% |
| 101 to 250 | 3 | 6% |
| 1,001 to 5,000 | 1 | 2% |
| 5,001 to 10,000 | 1 | 2% |
Table 9. Biotech startups that raised Series B in San Diego, California by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series B and its headquarters is in San Diego, California. On 16 November 2026 that is 53 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 10 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 53 rows: 0 have no round amount, 0 no city and 4 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in San Diego, California whose last round is Series B are on the list?
- 53, in the file dated 16 November 2026. 11 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 53 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.